{"id":38225,"date":"2026-04-01T11:08:42","date_gmt":"2026-04-01T10:08:42","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=38225"},"modified":"2026-04-01T08:48:57","modified_gmt":"2026-04-01T07:48:57","slug":"zayiflama-ignesi-kalp-hastalarina-nhste-sunulacak","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/zayiflama-ignesi-kalp-hastalarina-nhste-sunulacak\/","title":{"rendered":"Zay\u0131flama i\u011fnesi kalp hastalar\u0131na NHS\u2019de sunulacak"},"content":{"rendered":"

\u0130ngiltere\u2019de zay\u0131flama i\u011fnesi Wegovy<\/strong>, kalp krizi ve fel\u00e7 riski ta\u015f\u0131yan hastalara NHS kapsam\u0131nda sunulacak.<\/p>\n

Y\u00fcksek risk grubuna yeni tedavi<\/h4>\n

BBC\u2019nin haberine g\u00f6re, sa\u011fl\u0131k otoritesi NICE<\/strong>, kalp hastal\u0131\u011f\u0131 bulunan veya ciddi dola\u015f\u0131m sorunlar\u0131 ya\u015fayan ve fazla kilolu olan ki\u015filere haftal\u0131k enjeksiyonun verilmesini \u00f6nerdi.<\/p>\n

Tedavi, mevcut ila\u00e7lara ek olarak \u201cek bir koruma katman\u0131\u201d olarak de\u011ferlendiriliyor. Hastalar\u0131n uygunlu\u011fu, doktorlar taraf\u0131ndan bireysel olarak de\u011ferlendirilecek.<\/p>

\"\"<\/a><\/div>\n

Riskte %20\u2019ye varan d\u00fc\u015f\u00fc\u015f<\/h4>\n

Klinik ara\u015ft\u0131rmalar, semaglutid etken maddesini i\u00e7eren Wegovy\u2019nin, kalp krizi ve fel\u00e7 riskini yakla\u015f\u0131k %20 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131<\/strong> ortaya koydu.<\/p>\n

Uzmanlar, ilac\u0131n etkisinin yaln\u0131zca kilo kayb\u0131na ba\u011fl\u0131 olmad\u0131\u011f\u0131n\u0131, do\u011frudan kalp ve damar sistemi \u00fczerinde de olumlu etkiler yaratt\u0131\u011f\u0131n\u0131<\/strong> belirtiyor.<\/p>\n

Uygulama yaz aylar\u0131nda ba\u015flayacak<\/h4>\n

Tedavinin bu yaz itibar\u0131yla ba\u015flat\u0131lmas\u0131 planlan\u0131yor. Hastalar, ilac\u0131 \u00f6zel bir kalem enjekt\u00f6r arac\u0131l\u0131\u011f\u0131yla evde kendi kendine uygulayabilecek<\/strong>.<\/p>\n

Wegovy, v\u00fccutta tokluk hissini art\u0131ran GLP-1 hormonunu taklit ederek i\u015ftah\u0131 azalt\u0131yor ve sindirimi yava\u015flat\u0131yor. Ancak baz\u0131 hastalarda mide bulant\u0131s\u0131 ve \u015fi\u015fkinlik<\/strong> gibi yan etkiler g\u00f6r\u00fclebiliyor.<\/p>\n

Ya\u015fam tarz\u0131 de\u011fi\u015fikli\u011fi vurgusu<\/h4>\n

Uzmanlar, ilac\u0131n tek ba\u015f\u0131na yeterli olmad\u0131\u011f\u0131n\u0131 ve sa\u011fl\u0131kl\u0131 beslenme ile d\u00fczenli egzersizin<\/strong> tedavinin \u00f6nemli bir par\u00e7as\u0131 oldu\u011funu vurguluyor.<\/p>\n

NHS kapsam\u0131nda tedavi s\u00fcresi \u015fu an i\u00e7in iki y\u0131l ile s\u0131n\u0131rl\u0131<\/strong> tutulurken, uzun vadeli etkiler \u00fczerine ara\u015ft\u0131rmalar s\u00fcr\u00fcyor.<\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

\u0130ngiltere\u2019de zay\u0131flama i\u011fnesi Wegovy, kalp krizi ve fel\u00e7 riski ta\u015f\u0131yan hastalara NHS kapsam\u0131nda sunulacak. Y\u00fcksek risk grubuna yeni tedavi BBC\u2019nin haberine g\u00f6re, sa\u011fl\u0131k otoritesi NICE, kalp hastal\u0131\u011f\u0131 bulunan veya ciddi dola\u015f\u0131m sorunlar\u0131 ya\u015fayan ve fazla kilolu olan ki\u015filere haftal\u0131k enjeksiyonun verilmesini \u00f6nerdi. Tedavi, mevcut ila\u00e7lara ek olarak \u201cek bir koruma katman\u0131\u201d olarak de\u011ferlendiriliyor. Hastalar\u0131n uygunlu\u011fu, doktorlar taraf\u0131ndan bireysel olarak de\u011ferlendirilecek. Riskte %20\u2019ye varan d\u00fc\u015f\u00fc\u015f Klinik ara\u015ft\u0131rmalar, semaglutid etken maddesini i\u00e7eren Wegovy\u2019nin, kalp krizi ve fel\u00e7 riskini yakla\u015f\u0131k %20 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131 ortaya koydu. Uzmanlar, ilac\u0131n etkisinin yaln\u0131zca kilo kayb\u0131na ba\u011fl\u0131 olmad\u0131\u011f\u0131n\u0131, do\u011frudan kalp ve damar sistemi \u00fczerinde de olumlu etkiler yaratt\u0131\u011f\u0131n\u0131 […]<\/p>\n","protected":false},"author":11,"featured_media":34706,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[5269,15,13],"tags":[],"class_list":["post-38225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-birlesik-krallik","category-ingiltere","category-saglik"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/38225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=38225"}],"version-history":[{"count":2,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/38225\/revisions"}],"predecessor-version":[{"id":38228,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/38225\/revisions\/38228"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/34706"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=38225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=38225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=38225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}